Most people experience some side effects on semaglutide or tirzepatide — but most are manageable. This guide gives you evidence-based strategies to stay on treatment and get results.
Key insight: Side effects are most common during dose escalation phases. Once you stabilize at a dose, the GI symptoms — especially nausea — typically subside significantly for most people. Staying on treatment long enough to reach that stability is the goal.
The #1 reason people discontinue GLP-1 therapy — and also the most manageable with the right approach. It results from slowed gastric emptying, which is the same mechanism that reduces appetite.
GI motility changes are common. Some people experience diarrhea, others constipation — and some cycle between both. Usually improves after dose stabilization.
Fatigue often reflects reduced caloric intake — your body is running on fewer calories and may feel it, especially in early weeks. Can also be compounded by GI disruption affecting sleep and nutrition.
Usually occurs at new higher doses and resolves once the dose stabilizes. If vomiting is frequent, it requires medical attention to prevent dehydration and electrolyte imbalance.
Redness, itching, bruising, or small lumps at the injection site are common and usually minor. Rarely a reason to discontinue.
A mild increase in resting heart rate (typically 1–4 bpm) has been observed in clinical trials for semaglutide and tirzepatide. Usually clinically insignificant, but worth monitoring if you have cardiac conditions.
Any significant calorie-restricted weight loss involves some lean mass loss — GLP-1 medications are no different. Studies suggest 25–40% of weight lost on these medications may come from lean mass, similar to other weight loss methods.
What actually helps preserve muscle:
Rapid or significant weight loss can change facial appearance — more prominent bone structure, reduced facial volume. This is a natural consequence of fat loss, not a drug-specific effect unique to GLP-1s. It occurs with any significant weight loss method. If it's a concern, the solution is pacing weight loss more gradually (which can be achieved through slower dose escalation) and maintaining adequate nutrition.
Temporary hair shedding is reported by some GLP-1 users and is well-documented with rapid weight loss in general. It occurs because physiological stress (rapid calorie restriction, nutritional changes) pushes hair follicles into a resting phase. Hair typically regrows once weight loss stabilizes. Ensuring adequate protein and micronutrient intake (especially zinc, iron, and biotin) can help minimize this effect.
Regulatory agencies (FDA, EMA) have reviewed reports of depression and suicidal ideation in GLP-1 users. As of 2025, the FDA concluded that the current evidence does not establish a causal link. However, because GLP-1 medications are used in a population with elevated rates of depression (obesity is associated with higher depression prevalence), monitoring is appropriate. If you notice new or worsening mood symptoms, contact your prescriber.
Mild nausea, reduced appetite, possible GI changes. Most people tolerate the starting dose well. Focus on small meals, hydration, and bedtime injection timing.
Each dose step-up commonly brings a return of GI symptoms for 1–3 weeks. This is expected and temporary. This is when most people who quit, quit — push through with management strategies or ask to slow the escalation schedule.
Side effects typically diminish significantly once you've been stable at a dose for 3–4 weeks. Appetite suppression remains; GI symptoms usually decrease. Energy levels tend to normalize.
Each escalation may bring a brief wave of GI symptoms. With experience, most people develop personal strategies that work. Food choices, meal timing, and injection timing become intuitive.
Most people at stable doses report minimal ongoing side effects. Some mild nausea may persist with large meals or high-fat foods. The body has adapted to the medication's effects on GI motility.
Both medications share similar side effect profiles, but there are some differences worth knowing:
| Side Effect | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Notes |
|---|---|---|---|
| Nausea | ~44% | ~31% | Tirzepatide may be slightly better tolerated |
| Diarrhea | ~30% | ~23% | Both improve after dose stabilization |
| Vomiting | ~9% | ~6% | Usually peaks with dose escalation |
| Constipation | ~11% | ~17% | Tirzepatide higher constipation rate |
| Fatigue | ~11% | ~13% | Nutritional — protein/hydration helps most |
| Injection site reaction | ~3% | ~7% | Rotation technique reduces frequency |
| Discontinuation due to GI AEs | ~4–5% | ~3–4% | Slow escalation reduces this significantly |
Sources: SUSTAIN trial series (semaglutide), SURMOUNT trial series (tirzepatide). Rates are approximate and vary across trials and doses.
Most side effects are expected and manageable. But some symptoms require prompt medical attention:
Standard escalation schedules are designed to work for most patients — not all. If you're struggling with side effects, slowing the escalation schedule is clinically appropriate and should not be viewed as failure.
| Standard Schedule | Extended Schedule (Side Effects) | When to Use Extended |
|---|---|---|
| 4 weeks per dose step | 6–8 weeks per dose step | Nausea/vomiting lasting more than 2 weeks at current dose |
| Escalate per fixed schedule | Stay until symptoms resolve first | Any dose step-up causing meaningful quality-of-life disruption |
| Reach target dose in ~16–20 weeks | Reach target dose in 24–36 weeks | People with sensitivity to GI medications or prior GI conditions |
Telehealth program tip: Many telehealth GLP-1 programs auto-escalate doses on a fixed schedule. You have the right to tell your prescriber that you want to stay at your current dose longer before escalating. This is a medically legitimate request — and the slowest tolerated dose that achieves your goals is the right dose for you.
For weekly GLP-1 medications, you can shift the injection day by up to 2–3 days without affecting efficacy, as long as it's been at least 4 days since your last injection. If you're currently experiencing nausea or illness, waiting an extra day or two is reasonable — but discuss with your prescriber if you're unsure.
If you need to stop GLP-1 therapy, expect that a meaningful amount of weight will return over time. The STEP-4 trial showed approximately two-thirds of lost weight returned within 52 weeks of stopping semaglutide. See our GLP-1 Stopping Guide for strategies to manage this transition.
Yes — the period around each dose increase is typically the most challenging. If you can get to a stable dose and give your body 3–4 weeks to adjust, most people find that side effects become much more manageable. The people who succeed on GLP-1 therapy are often those who pushed through the first 8–12 weeks.
Alcohol is not strictly contraindicated with GLP-1 medications, but it amplifies nausea and GI side effects significantly. Many people find they tolerate alcohol much less well on GLP-1 therapy — smaller amounts cause greater effects. Additionally, for people on GLP-1s for diabetes, alcohol can complicate blood sugar management. General guidance: minimize or eliminate alcohol during the first several months of treatment.
Side effects are caused by the same mechanism (slowed gastric emptying) that drives the medication's effectiveness — but they are not required for efficacy. Someone with minimal side effects can still achieve excellent weight loss results. Side effects are not a marker of "it's working." They're simply an indication that your GI system is responding to the medication and needs time to adapt.